Ranked by reported Q2 2026 13F market value
Share of total reported institutional value in DYN held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 12.4M | $275.5M | +6.0% | 6.642% | 0.00% |
| 2 | Jupiter Topco LLC | 12.0M | $266.6M | — | 6.425% | 0.11% |
| 3 | FMR LLC | 11.2M | $248.9M | +25.8% | 6.001% | 0.01% |
| 4 | STATE STREET CORP | 7.5M | $165.6M | +12.1% | 3.994% | 0.00% |
| 5 | Orbis Allan Gray Ltd | 7.0M | $155.6M | +3.6% | 3.752% | 0.53% |
| 6 | Atlas Venture Life Science Advisors, LLC | 6.8M | $151.0M | -25.5% | 3.641% | 17.14% |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 6.3M | $140.2M | -1.5% | 3.379% | 0.00% |
| 8 | TCG Crossover Management, LLC | 4.6M | $102.5M | 0.0% | 2.471% | 2.46% |
| 9 | VANGUARD PORTFOLIO MANAGEMENT LLC | 4.0M | $89.9M | -2.7% | 2.168% | 0.00% |
| 10 | FCPM III SERVICES B.V. | 3.8M | $85.5M | -17.1% | 2.061% | 11.39% |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 3.7M | $83.2M | +6.8% | 2.005% | 0.00% |
| 12 | Vestal Point Capital, LP | 3.4M | $75.0M | -15.6% | 1.807% | 1.75% |
| 13 | ORBIMED ADVISORS LLC | 3.2M | $71.9M | +10.9% | 1.733% | 1.33% |
| 14 | Frazier Life Sciences Management, L.P. | 3.2M | $70.0M | 0.0% | 1.688% | 1.53% |
| 15 | ARMISTICE CAPITAL, LLC | 3.1M | $68.6M | -2.8% | 1.653% | 0.84% |
| 16 | JPMORGAN CHASE & CO | 3.2M | $67.2M | -3.1% | 1.688% | 0.00% |
| 17 | PERCEPTIVE ADVISORS LLC | 2.7M | $59.7M | -42.4% | 1.440% | 0.90% |
| 18 | Logos Global Management LP | 2.5M | $56.6M | +82.1% | 1.365% | 2.44% |
| 19 | BANK OF AMERICA CORP /DE/ | 2.2M | $49.6M | +54.7% | 1.196% | 0.00% |
| 20 | Venrock Adviser, LLC | 2.2M | $48.3M | 0.0% | 1.164% | 1.46% |
| 21 | GOLDMAN SACHS GROUP INC | 2.2M | $47.9M | +25.2% | 1.155% | 0.00% |
| 22 | Siren, L.L.C. | 2.1M | $47.3M | -4.5% | 1.140% | 0.96% |
| 23 | FRANKLIN RESOURCES INC | 2.0M | $45.1M | +1.1% | 1.087% | 0.01% |
| 24 | DIMENSIONAL FUND ADVISORS LP | 1.9M | $43.2M | +104.6% | 1.042% | 0.01% |
| 25 | MPM BioImpact LLC | 1.9M | $42.7M | +36.5% | 1.029% | 2.60% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in DYN — a direct measure of their conviction.
Filings activity in DYN during Q2 2026, grouped by how each filer changed its position.
8 quarters of 13F filings · Δ columns show change vs prior quarter
| Quarter | Inst. Holders | Δ Holders | Ownership % | Δ Ownership | Total 13F Value | Δ Value |
|---|---|---|---|---|---|---|
| Q2 2026 | 249 | +7.8% | 102.20% | +1.16 pp | $3.46B | +23% |
| Q1 2026 | 231 | +0.9% | 101.04% | +13.16 pp | $2.80B | 8.8% |
| Q4 2025 | 229 | +12% | 87.88% | 9.29 pp | $3.08B | +61% |
| Q3 2025 | 205 | +4.1% | 97.17% | 2.59 pp | $1.91B | +63% |
| Q2 2025 | 197 | 3.0% | 99.76% | +6.86 pp | $1.17B | 2.8% |
| Q1 2025 | 203 | +3.0% | 92.90% | 1.49 pp | $1.21B | 52% |
| Q4 2024 | 197 | 2.0% | 94.39% | 2.49 pp | $2.50B | 34% |
| Q3 2024 | 201 | — | 96.88% | — | $3.81B | — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
Quick answers to the most common questions about buying DYN stock.
Based on Q2 2026 13F filings, institutional ownership of Dyne Therapeutics, Inc. stands at 102.2%, held across 249 reporting institutions.
BlackRock, Inc. is the largest reported institutional holder of DYN, with approximately 12,404,330 shares worth $0.28B as of Q2 2026.
No marquee "smart money" managers (Berkshire, Burry, ARK, Tiger Global, Pershing Square, Baupost, etc.) currently appear among the top 25 institutional holders of DYN.
Our composite Smart Money Score for DYN is 50 out of 100 (Neutral). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
43 institutions opened new positions in DYN during Q2 2026, while 29 fully exited. 166 added to existing positions and 32 trimmed.
DYN institutional ownership rose by 1.16 percentage points quarter-over-quarter, with a net change of +18 holders.
The top 10 institutions account for 48.6% of all reported 13F value in DYN, and the top 25 account for 74.0%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.
Dyne Therapeutics, Inc. (DYN) Institutional Ownership